Physician profile
Arshia Rassi
NPI 1306225750
$7,214.31
in general payments reported to CMS, 2019-2025
20 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.41 · 2020: $93.46 · 2021: $6,072 · 2022: $157 · 2023: $139 · 2024: $368 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,000.00 | 2021 | |
| Hologic Sales and Service, LLC | $194.17 | 2024-2025 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| Sage Therapeutics, LLC | $145.16 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $115.50 | 2019-2024 | Injectafer |
| Coloplast Corp | $109.11 | 2024 | |
| Ucb, INC. | $104.84 | 2025 | |
| Coopersurgical, INC. | $82.74 | 2020-2024 | Summit Doppler |
| Merck Sharp & Dohme LLC | $80.02 | 2020-2024 | Gardasil 9, Gardasil |
| Organon LLC | $75.34 | 2022-2024 | Nexplanon |
| Abbvie INC. | $51.77 | 2019-2023 | |
| Pfizer INC. | $48.19 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.55 | 2020-2022 | |
| Astellas Pharma US INC | $32.65 | 2023 | Veozah |
| Exact Sciences Corporation | $29.31 | 2023 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $22.01 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $20.46 | 2024 | Myfembree |
| Medtronic, INC. | $19.64 | 2022 | |
| Minerva Surgical, INC | $18.25 | 2023 | |
| Supernus Pharmaceuticals, INC. | $14.92 | 2025 | Qelbree |
| Myovant Sciences INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshia Rassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.